Fennec Pharmaceuticals Inc. (NASDAQ: FENC ) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.
Analysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core & Main's quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro .
On March 16, Fennec Pharmaceuticals announced a settlement agreement resolving PEDMARK patent litigation.
Fennec Pharmaceuticals shares gained 1.8% to close at $7.45 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
Considering buying FENC stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Earnings News Price Target Markets Analyst Ratings Trading Ideas Expert Ideas Most Accurate Analysts